ES361702A1 - Dihydroorotic and Salts - Google Patents
Dihydroorotic and SaltsInfo
- Publication number
- ES361702A1 ES361702A1 ES361702A ES361702A ES361702A1 ES 361702 A1 ES361702 A1 ES 361702A1 ES 361702 A ES361702 A ES 361702A ES 361702 A ES361702 A ES 361702A ES 361702 A1 ES361702 A1 ES 361702A1
- Authority
- ES
- Spain
- Prior art keywords
- improve
- hydroxy
- amino
- dihydroorotic
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 230000036626 alertness Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- UFIVEPVSAGBUSI-UHFFFAOYSA-N dihydroorotic acid Chemical compound OC(=O)C1CC(=O)NC(=O)N1 UFIVEPVSAGBUSI-UHFFFAOYSA-N 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- -1 hydroxy, carboxy, amino Chemical group 0.000 abstract 1
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
- 239000011707 mineral Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000008024 pharmaceutical diluent Substances 0.000 abstract 1
- 125000003595 primary aliphatic amine group Chemical group 0.000 abstract 1
- 150000005619 secondary aliphatic amines Chemical class 0.000 abstract 1
- 150000003510 tertiary aliphatic amines Chemical class 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Pharmaceutical compositions comprise at least one salt of dihydro-orotic acid with a primary, secondary or tertiary aliphatic amine containing at least one other hydrophilic group selected from hydroxy, esterified hydroxy, carboxy, amino or carbamoyl, in the molecule together with a pharmaceutical carrier or diluent and optionally vitamins, minerals, amino acids or enzymes. They may be administered orally, rectally, parenterally or topically and are used to improve the flow of blood through the capillaries and vascular system as well as to improve the depth of sleep, level of depression and exhaustion and alertness.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB5814067A GB1182320A (en) | 1967-12-21 | 1967-12-21 | Dihydroorotic and Salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES361702A1 true ES361702A1 (en) | 1970-11-16 |
Family
ID=10480857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES361702A Expired ES361702A1 (en) | 1967-12-21 | 1968-12-20 | Dihydroorotic and Salts |
Country Status (7)
| Country | Link |
|---|---|
| BE (1) | BE725874A (en) |
| CH (1) | CH510674A (en) |
| DE (1) | DE1816097A1 (en) |
| ES (1) | ES361702A1 (en) |
| FR (1) | FR8234M (en) |
| GB (1) | GB1182320A (en) |
| NL (1) | NL6818217A (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3912477A1 (en) * | 1989-04-15 | 1990-10-18 | Mueller Robert Dr | OUTSTANDING PRAEPARATE AND ITS USE |
| US7396526B1 (en) | 1998-11-12 | 2008-07-08 | Johnson & Johnson Consumer Companies, Inc. | Skin care composition |
| US6607735B2 (en) | 2000-12-21 | 2003-08-19 | Johnson & Johnson Consumer Companies, Inc. | Method for reducing the appearance of dark circles under the eyes |
| US20040254202A1 (en) * | 2003-06-13 | 2004-12-16 | The Procter & Gamble Company | Method of promoting sleep using topical administration of vasoactive agents |
-
1967
- 1967-12-21 GB GB5814067A patent/GB1182320A/en not_active Expired
-
1968
- 1968-12-18 NL NL6818217A patent/NL6818217A/xx unknown
- 1968-12-19 CH CH1891168A patent/CH510674A/en not_active IP Right Cessation
- 1968-12-19 FR FR179091A patent/FR8234M/fr not_active Expired
- 1968-12-20 DE DE19681816097 patent/DE1816097A1/en active Pending
- 1968-12-20 ES ES361702A patent/ES361702A1/en not_active Expired
- 1968-12-20 BE BE725874D patent/BE725874A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE1816097A1 (en) | 1969-09-25 |
| BE725874A (en) | 1969-06-20 |
| NL6818217A (en) | 1969-06-24 |
| CH510674A (en) | 1971-07-31 |
| FR8234M (en) | 1970-09-28 |
| GB1182320A (en) | 1970-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1291631A (en) | Triazolobenzodiazepine derivatives | |
| GB1341058A (en) | Polyether amines their production and use | |
| GB1221393A (en) | Improvements in or relating to hepato-protective drugs | |
| ES341109A1 (en) | Substituted ammonium basic addition salts of ribonucleic acid | |
| GB1054104A (en) | ||
| GB1182320A (en) | Dihydroorotic and Salts | |
| GB1297080A (en) | ||
| GB1195200A (en) | Pharmaceutical Compositions. | |
| GB1125349A (en) | Soluble salts of ellagic acid | |
| GB1051686A (en) | ||
| ES375079A1 (en) | 3-alkoxy-or 3-aryloxy-2-(diaryl-hydroxy)-methyl-propylamines | |
| GB1210968A (en) | Improvements in or relating to the treatment of gastric ailments | |
| GB1252286A (en) | ||
| GB980436A (en) | The acid salt composed of acetyl glutamic acid and n,n-dimethylaminoethanol-1 and preparation of same | |
| GB1290300A (en) | ||
| ES361305A1 (en) | Diazepine derivatives of dithiocarboxylates as dopamine - beta - hydroxylase inhibitors | |
| GB1208798A (en) | Production of polyquinazolones | |
| GB1250279A (en) | ||
| GB1336609A (en) | Antismoking preparation | |
| GB1424611A (en) | Pharmaceutical compositions | |
| GB1261660A (en) | alpha-HYDRAZINO ACIDS | |
| GB1357300A (en) | Magnesium salts | |
| GB1312129A (en) | Antibiotic and process for preparing same | |
| GB1208814A (en) | Trans-dihydroxy-bis-hydroxycarbonylethylene salts | |
| GB1386927A (en) | Preparations for combatting swine dysentery |